What changed in this filing

/stocks — the workspaceLOADING

Item 5. Other Information

2021-07-30 compared with 2021-05-14 · 20 added, 18 removed, 28 unchanged (58% of the section changed)

OTHER INFORMATION.

Copies of the following documents

are included as exhibits to this report pursuant to Item 601 of Regulation S-K.

26, 2021, Dale Ludwig resigned as the Company’s Chief Scientific and Technology Officer.

Ludwig’s resignation is not

the result of any disagreement with the Company or its Board of Directors or any matter relating to the Company’s operations, policies,

or practices.

of the following documents are included as exhibits to this report pursuant to Item 601 of Regulation S-K.

Title of Document

Certificate of Incorporation of Actinium Pharmaceuticals, Inc.

(incorporated by reference to Exhibit 3.1 of the Company’s Form 8-K filed with the SEC on April 17, 2013).

Certificate of Amendment to Certificate of Incorporation, as amended, filed January 7, 2014 (incorporated by reference to Exhibit 3.5 to Form S-1 filed on January 31, 2014).

20 unchanged sentences

XBRL Taxonomy Presentation Linkbase Document

Exhibit attached to this Form 10-Q shall not be deemed “filed”

for purposes of Section 18 of the Securities Exchange

Act of 1934 (the “Exchange Act”) or otherwise subject to liability under that section, nor shall it be deemed incorporated

by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by

specific reference in such filing.

Pursuant to the requirements

of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto

duly authorized.

ACTINIUM PHARMACEUTICALS, INC.

/s/ Sandesh Seth

Chairman and Chief Executive Officer

Cover Page Interactive Data file (formatted as Inline XBRL and contained

in Exhibit 101)

Exhibit attached to this Form 10-Q shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act

of 1934 (the “Exchange Act”) or otherwise subject to liability under that section, nor shall it be deemed incorporated by

reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific

reference in such filing.

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by

the undersigned thereunto duly authorized.

PHARMACEUTICALS, INC.

July 30, 2021

and Chief Executive Officer

(Duly Authorized Officer and

Principal Executive Officer)

/s/ Steve O’Loughlin

Steve O’Loughlin

Chief Financial Officer

(Duly Authorized Officer and

Steve O’Loughlin

Financial Officer

Authorized Officer and

Principal Financial and Accounting Officer)

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q

Item 5. Other Information